How florbetapir could accelerate Alzheimer's research

03/7/2013 | MolecularImaging.net

The practice of beta-amyloid imaging to help diagnose Alzheimer's disease, while slowly evolving, still faces challenges and uncertainties, experts say. Health care providers are hesitant to adopt the use of scans with florbetapir because the procedure is not reimbursed by Medicare and private insurers, in part because of concerns about how the tests will affect patient management. However, the reimbursement question is likely to be resolved by the end of the year, and experts are hopeful increased utilization of the imaging tests will funnel more patients into clinical trials, accelerating research into therapies.

View Full Article in:

MolecularImaging.net

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Market Access Manager Electrophysiology HEOR (AEP) - 15000003NZ
Abbott
Menlo Park, CA
Sales Manager, Employer Programs
PartnerRe Health